Media ReleasesNyrada

View All Nyrada News


Nyradas NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction in Preclinical Study


Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announces encouraging efficacy results from its in vivo study of NYX-PCSK9i in a specialised mouse model, called APOE*3 Leiden.CETP. The results support the selection of NYX-PCSK9i as the preferred compound for preclinical studies at an internationally recognised Contract Research Organisation, ahead of a Phase 1 first-in-human study.

Results from an in vivo efficacy study in a specialised mouse model showed NYX-PCSK9i reduced total cholesterol by 46% as a monotherapy, and 65% when dosed in combination with the statin drug Lipitor over the study period. This compares to the reduction achieved using Lipitor alone of 27% (see Figure 1 and Table 1 below). Since it was approved in 1997, Lipitor has been the best selling drug worldwide generating lifetime sales of US$164 billion. It was also the most prescribed drug in Australia in 2020.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.